A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
IKS Health completes $557M TruBridge acquisition
Andrew Cass / beckershospitalreview - IKS Health has completed its $557 million acquisition of TruBridge, which provides revenue cycle management and EHR services for rural and community hospitals. Following the closing, TruBridge operates as a wholly owned subsidiary of IKS Health, according…
AI Summary: IKS Health has closed a $557 million deal to acquire TruBridge, integrating the acquired firm’s revenue-cycle and IT capabilities into IKS’s technology stack. The purchase accelerates IKS’s push to expand managed services for health systems, promising greater scale and product consolidation—because nothing says progress like buying your way into the future.
Ascension to Buy Tennessee Health System for Nearly $1B
Katie Adams / medcitynews - Ascension is set to acquire Williamson Health, a county-owned health system in Tennessee, in a deal worth nearly $1 billion. Ascension’s offer beat out bids from HCA Healthcare and Optum. The post Ascension to Buy Tennessee Health System for Nearly $1B ap…
AI Summary: Ascension announced plans to buy Williamson Health, an independent Tennessee health system, in a transaction valued at roughly $700M–$1B. The acquisition further consolidates hospital ownership in the region and will shift local governance and operational control to Ascension as the parties work through regulatory and integration steps.
American Hospital Association names Steve Walsh as next CEO
fiercehealthcare - Walsh is currently the head of the Massachusetts Hospital Association, and will be taking the national stage at a moment of substantial policy and political challenges for the hospital industry.
AI Summary: Steve Walsh was named the next CEO of the American Hospital Association, replacing outgoing leadership and signaling continuity with a public-sector advocacy background. The appointment centers on navigating hospital policy, membership priorities and advocacy at a time of industry consolidation and regulatory pressure — yes, more meetings and memos ahead.
As PBM industry shifts, LucyRx and Abarca Health merge to build scale
fiercehealthcare - Amid significant shifts in the pharmacy benefit management industry, LucyRx and Abarca Health have revealed plans to merge to build the scale necessary to compete in this changing landscape.
AI Summary: Two independent pharmacy benefit managers, LucyRx and Abarca Health, announced a combination to build scale amid industry consolidation. The deal aims to bolster negotiating leverage, broaden client reach and offer an alternative to dominant PBMs—because apparently one disruptor wasn’t enough to disrupt the disruptors.
Lifepoint closes acquisition of 8 ScionHealth hospitals
Kelly Gooch / beckershospitalreview - Brentwood, Tenn.-based Lifepoint Health has completed its acquisition of eight community hospitals from Louisville, Ky.-based ScionHealth. The hospitals are spread across six states, according to a June 2 news release. Lifepoint acquired: Lifepoint origin…
AI Summary: Lifepoint Health has finalized its purchase of eight community hospitals previously held by ScionHealth, consolidating regional services under a larger system. The deal promises operational integration and potential investment but also raises typical concerns about community access, continuity of care and how local staff will fare under new management.
Ascension must sell 7 ASCs to complete $3.9B AmSurg deal: FTC
Alan Condon / beckershospitalreview - St. Louis-based Ascension has received Federal Trade Commission approval to move forward with its planned acquisition of AmSurg — an ambulatory surgery center operator with more than 250 facilities across 34 states — but only after agreeing to divest seve…
AI Summary: The Federal Trade Commission approved Ascension’s $3.9 billion acquisition of AmSurg only after ordering divestitures of specific ambulatory surgery centers to preserve competition. Ascension must sell those ASCs before closing to prevent local market concentration and potential price hikes — because apparently somebody still has to protect patients from monopolies.
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
Quorum Health strikes deal to become nonprofit
Kelly Gooch / beckershospitalreview - Quorum Health, a for-profit system headquartered in Brentwood, Tenn., has signed a definitive agreement with nonprofit health system Healthside Partners to transition Quorum into a nonprofit organization spanning 11 hospitals across nine states. With the …
AI Summary: Quorum Health agreed to become a nonprofit through a transaction with Healthside Partners to avert insolvency, rescue struggling hospitals, and stabilize finances. Executives frame the conversion as a survival strategy to maintain care access, restructure operations, and shift priorities from profitability to community health amid mounting fiscal pressure.
GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor
Reynald Castaneda / endpoints - European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion. In a Wednesday release, they said ...
AI Summary: GHO Capital and CBC Group have agreed to combine their healthcare investment platforms to create roughly a $21 billion specialist investor focused on health assets. The tie-up consolidates capital and deal teams to chase larger transactions across care delivery, pharma and tech—because apparently healthcare needed a bigger private-equity behemoth.
Healthcare bankruptcies increased 33% in Q1: 6 things to know
Andrew Cass / beckershospitalreview - Healthcare Chapter 11 bankruptcy filings rose to 12 cases in the first quarter of 2026, up from 9 cases in the fourth quarter of 2025, according to an April report by Gibbins Advisors. The report analyzed Chapter 11 bankruptcy filings with liabilities of …
AI Summary: A new report finds healthcare bankruptcies rose 33% in the first quarter, underscoring mounting financial pressure across providers from squeezed margins, rising expenses and a tricky reimbursement environment. The surge raises concerns about patient access, consolidation and creditor fallout, and suggests policymakers and executives may need to stop pinching pennies and start fixing structural problems.
- Budgeting, Labor and Management Fixes Under Strain (5)
- Closures, Downgrades and State Rescue Responses (4)
- Q1 Bankruptcy Surge: Numbers and Sector Breakdown (3)
- All Other Stories
Budgeting, Labor and Management Fixes Under Strain
Closures, Downgrades and State Rescue Responses
Q1 Bankruptcy Surge: Numbers and Sector Breakdown
All Other Stories
UCB bets $2 billion on Candid's T cell engager ambitions
Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...
AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.
Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
fiercehealthcare - The deal, expected to close later this year, is another attempt from the major rural nonprofit system to enter the Minneapolis market. To do so, it plans a $600 million investment into two-hospital North Memorial Health that will help stabilize one financ…
AI Summary: Sanford Health announced a plan to integrate Minnesota-area North Memorial Health with a $600 million investment, creating a combined system aimed at expanding services, streamlining care and gaining scale. The transaction is part of a broader wave of regional healthcare consolidation as systems chase efficiency and market presence.
Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
fiercehealthcare - The deal would bring the 40-year-old, publicly traded company under a growth-oriented investment firm with a prior background in healthcare staffing.
AI Summary: Staffing firm Cross Country Healthcare agreed to be taken private in a $437 million deal by private equity buyer Knox Lane, ending its public-company chapter. The acquisition positions the firm for strategic repositioning and could reverberate across hospital staffing markets as investors consolidate workforce services.
WakeMed Health's plans to join Atrium Health face swift pushback from NC officials
fiercehealthcare - A combination unveiled May 1 would bring WakeMed Health $2 billion in promised investment from the major nonprofit system. State officials voiced concerns about the impact of such consolidation and the value of those commitments, delaying a planned go-ahe…
AI Summary: Atrium Health’s plan to fold WakeMed into its system — backed by a roughly $2 billion investment plan — is running into immediate resistance from North Carolina officials. State leaders and local stakeholders have raised concerns about consolidation, competition and community impact, threatening regulatory scrutiny that could delay or reshape the deal. Expect tense negotiations, press statements and a few dramatic headlines.
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Kyle LaHucik / endpoints - Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...
AI Summary: Chiesi Group agreed to buy KalVista for $1.9 billion to secure an approved therapy and expand its rare-disease footprint. The deal transfers marketed assets and R&D capacity, positioning Chiesi to scale rare-disease revenues and invest in next-wave therapeutics — essentially a big check for a bigger strategic play.
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…
AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.
Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution
oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]
AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.
Orlando Health fleshes out Alabama footprint with another acquisition
fiercehealthcare - The $10 billion nonprofit plans to acquire RMC Health System from the City of Anniston, building on 2024's big-ticket purchase of five Alabama hospitals from Tenet Healthcare.
AI Summary: Orlando Health continued its regional growth by acquiring an Alabama health system, extending its clinical and operational footprint into the state. The move aims to integrate services, expand care access and consolidate regional networks as health systems seek scale to manage costs and enhance specialty offerings.
Hospital M&A roars back to life in Q1 2026; Operating performances fray in February
fiercehealthcare - The first quarter of 2026 extended a recovery from last year's dealmaking slowdown with 22 newly announced transactions, largely fueled by divestitures. Meanwhile, February benchmarking data outlined persistent operating pressures and soft volumes.
AI Summary: Hospital merger and acquisition activity rebounded sharply in Q1 2026 after a 2025 slowdown, driven by systems seeking scale to manage financial stress. Reports show operating performance weakened in February, prompting consolidation as a survival strategy; expect more deal-making as health systems chase efficiencies and revenue stability in a tight market.
- Closures and bailouts: struggling hospitals prompt local interventions (3)
- Local deals: hospitals change hands, campuses expand, LOIs signed (4)
- M&A resurgence: systems consolidate as operating pressure mounts (5)
- Operational fixes: CEOs tighten capital, redefine growth, stabilize workforce (5)
- All Other Stories